Previous close | 173.20 |
Open | 173.20 |
Bid | 170.45 |
Ask | 172.50 |
Strike | 250.00 |
Expiry date | 2024-06-21 |
Day's range | 135.27 - 173.20 |
Contract range | N/A |
Volume | |
Open interest | N/A |
China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue. Three Chinese companies - Walvax Biotechnology, CSPC Pharmaceutical Group and Stemirna Therapeutics - came up with mRNA vaccines that won limited emergency approvals in Asia. However, Walvax and CSPC are not currently manufacturing three of their China market shots, a China health official told Reuters.
In the latest trading session, Moderna (MRNA) closed at $103.44, marking a -0.34% move from the previous day.
Brad Miller is helping Moderna shift from its reliance on COVID vaccines, with the company hoping to introduce up to 15 new drugs over a five-year period.